NCT04728646View on ClinicalTrials.gov

Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2021

Primary Completion Date

December 13, 2021

Study Completion Date

December 13, 2021

Conditions
Graft Vs Host Disease
Interventions
DRUG

DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use

Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)

DEVICE

Regular dissolvable intracanalicular plug

Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)

Trial Locations (1)

02114

Mass Eye and Ear, Boston

Sponsors

Collaborators (1)

Ocular Therapeutix, Inc.
All Listed Sponsors
collaborator

Ocular Therapeutix, Inc.

INDUSTRY

lead

Massachusetts Eye and Ear Infirmary

OTHER